medigraphic.com

2009, Number 5

<< Back Next >>

Cir Cir 2009; 77 (5)

Desensibilización y trasplante renal. Plasmaféresis-IVIG a dosis estándar en pacientes con alto riesgo inmunológico

Flores-Gama F, Mondragón-Ramírez GA, Bochicchio-Riccardelli T

Language: Spanish
References: 36
Page: 369-374
PDF size: 95.53 Kb.


ABSTRACT

Background: Patients with high immunological risk have been relegated to the growing waiting list for an immunologically compatible donor. Our objective was to report the experience of a transplant center in desensitization of patients with high immunological risk.
Methods: We carried out a descriptive and retrospective study. Included were all the renal transplant patients from November 1999 to January 2008 in which we used plasmapheresis and standard dose of intravenous immunoglobulin (IVIG) as desensitization.
Results: Eight patients had history of alloimmunity (positive crossmatch or high panel-reactive antibodies, PRA ›30%). Desensitization was accomplished with plasmapheresis and exchange of 1.5 plasma volume. Subsequent to each session we administered a standard dose of IVIG (5 g/dose). Immunosuppression began equal to the first plasmapheresis with calcineurin inhibitor (tacrolimus) plus six patients with mycophenolate mofetil and two patients with sirolimus. In seven cases, negative crossmatches were obtained before the transplantation, except in the eighth case in whom it was not done. Two patients received human antibodies against CD25 (basiliximab, 20 mg/dose). During their evolution, all patients maintained stable graft function.
Conclusions: According to our experience, renal graft outcome in patients with high immunological risk after an adequate desensitization protocol is similar to that observed in nonsensitized patients, at least during the first year of transplantation.


REFERENCES

  1. Andree H, Nickel P, Nasiadko C, Hammer M, Schönemann C, Pruss A, et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006;17:573-580.

  2. Díaz I, Sánchez P, Alonso C, Valdés F. Immunological profile of patients awaiting a renal transplant. Clin Transpl 2004;18:529-535.

  3. Pour-Reza-Gholi F, Daneshvar S, Nafar M, Firouzan A, Farrokhi F, Einollahi B. Potential risk factors for hypersensitization reflected by panel-reactive antibodies in dialysis patients. Transplant Proc 2005;37:2936-2938.

  4. Sayegh M, Carpenter C. Transplantation 50 years later. Progress, challenges, and promises. N Engl J Med 2004;351:26.

  5. Centro Nacional de Trasplantes, Secretaría de Salud México. Estadísticas. Disponible en http://www.cenatra.salud.gob.mx/interior/trasplante_estadisticas.html

  6. Süsal C, Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Hum Immunol 2004;65:810-816.

  7. López-Hoyos M, Fernández-Fresnedo G, Rodrigo E, Ruiz J, Arias M. Effect of delayed graft function in hypersensitized kidney transplant recipients. Hum Immunol 2005;66:371-377.

  8. Montgomery R, Hardy M, Jordan S, Racusen L, Ratner Ll, Tyan D, et al. Consensus opinion from the Antibody Working Group on the Diagnosis, Reporting, and Risk Assessment for Antibody-Mediated Rejection and Desensitization Protocols. Transplantation 2004;78:181-185.

  9. Mahmoud K, Sobh M, El-Shenawy F, Isamil A, El-Magd M, Hassan N, et al. Can intravenous immunoglobulin and simvastatin solve the problem of sensitization in renal transplant candidates? Int Urol Nephrol 2007;39:979-981.

  10. Peraldi M, Kodzo A, Haymann JP, Flahaut A, Marlin C, Rondeau E, et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996;62:1670-1673.

  11. Sonnenday C, Ratner L, Zachary A, Burdick J, Samaniego M, Kraus E, et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002;34:1614-1616.

  12. Stegall M, Gloor J, Winters J, Moored S, DeGoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transpl 2006;6:346-351.

  13. Colovai A, Vasilescu ER. Intravenous immunoglobulin treatment in transplantation and autoimmune diseases. Hum Immunol 2005;66:333.

  14. Jordan S, Bunnapradist S, Toyoda M, Peng M, Puliyanda D, Kamil E, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in livingdonor and cadaver recipients. Transplantation 2003;76:631-636.

  15. Wang D, Chen J, Wu Z, Yang S, Wu G, Wang H, et al. One year results of preoperative single bolus ATG-fresenius induction therapy in sensitized renal transplant recipients. Transpl Proc 2007;39:69-72.

  16. Montgomery RA, Zachary A. Transplanting patients with a positive donorspecific crossmatch: a single center’s perspective. Pediatr Transplant 2004;8:535-542.

  17. Zachary A, Montgomery R, Leffell M. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005;66:364-370.

  18. Gloor J, Degoey S, Ploeger N, Gebel H, Bray R, Breanndan-Moore S, et al. Desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004;78:221-227.

  19. Gloor J, Degoey S, Pineda A, Moore AB, Prieto M, Nyberg S, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003;3:1017-1023.

  20. Le Conte P, Nicolas F, Adjou C, N’Guyen J, Billaud E, Moreau P. Replacement fluids in plasmapheresis: cross-over comparative study. Intensive Care Med 1997;23:342-344.

  21. Poggio E, Clemente M, Hricik D, Heeger P. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 2006;17:564-572.

  22. Lieber S, Pérez F, Tabossi M, Persoli L, Marques S, Mazzali M, et al. Effect of panel-reactive antibody in predicting crossmatch selection of cadaveric kidney recipients. Transpl Proc 2007;39:429-431.

  23. Schweitzer E, Wilson J, Fernández-Vina M, Fox M, Gutiérrez M, Wiland A, et al. A high panel-reactive antibody rescue protocol for cross-matchpositive live donor kidney transplants. Transplantation 2000;70:1530-1536.

  24. Akalin E, Pascual M. Sensitization after kidney transplantation. Clin J Am Soc Nephrol 2006;1:433-440.

  25. Bartel G, Wahrmann M, Exner M, Regele H, Schillinger M, Horl W, et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007;83:727-733.

  26. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui S, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins. Am J Transpl 2002;2:758-760.

  27. Panigrahi R, Deka D, Bhowmik S, Tiwari N, Mehra N. Immunological monitoring of posttransplant allograft sensitization following living related donor renal transplantation. Transpl Proc 2004;36:1336-1339.

  28. Urra J, De la Torre M, Alcazar R, Peces R, Ferreras I, García-Chico P. Variable in vitro inhibition of HLA-specific alloantibody-mediated cytotoxicity by intravenous human immunoglobulin. Transpl Proc 1998;30:4177-4179.

  29. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007;357:1293-1300.

  30. Akalin E, Bromberghuman J. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Immunology 2005;66:359-363.

  31. Bray R, Nolen J, Larsen C, Pearson T, Newell K, Kokko K, et al. Transplanting the highly sensitized patient: the Emory algorithm. Am J Transplant 2006;6:2307-2315.

  32. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998;66:1460-1464.

  33. Wong L, Laberge R, Harvey E, Filler G. Preventing sensitization with mycophenolate mofetil in a pediatric kidney recipient. Pediatr Transplant 2006;10:367-370.

  34. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003;76:395-400.

  35. Adeyi OA, Girnita AL, Howe J, Marrari M, Awadalla Y, Askar M, et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005;14:53-62.

  36. Inman B, Halloran B, Melk A, Ramassar V, Halloran P. Microchimerism in sensitized renal patients. Transplantation 1999;67:1381-1383.




2020     |     www.medigraphic.com